Accession Number:

ADA509742

Title:

Molecular Biology and Prevention of Endometrial Cancer

Descriptive Note:

Final addendum rept. 16 Jun 2008-16 Jun 2009

Corporate Author:

HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE ROCKVILLE MD

Personal Author(s):

Report Date:

2009-07-01

Pagination or Media Count:

7.0

Abstract:

To increase our understanding of the molecular aberrations associated with endometrial carcinogenesis and the biologic mechanisms underlying the protective effect of oral contraceptive OC therapy. Methods 1 Oligonucleotide microarray analysis was performed on a panel of endometrial cancers. 2 A subset of adenocarcinoma cases from the International DES Registry IDESR was analyzed for MSI 3 A case-control study of the CASH database was performed to evaluate the relationship between progestin potency and endometrial cancer risk. 4 An analysis of endometrium samples from cymologous macaques that were exposed to long term progestins was performed. 5 A clinical trial comparing progestin versus placebo is underway that will facilitate investigation of the effects of progestin exposure on the endometrial lining. Results 1 Different histological types of endometrial cancer have unique genomic expression patterns. 2 The poor quality DNA from the majority of IDESR samples prohibited an adequate analysis of the case set. 3 A case-control study has suggested higher progestin- potency OCs may be more protective than lower progestin potency OCs among women with a larger body habitus. 4 Macaque studies have suggested that induction of apoptosis may be a mechanism underlying the chemoprotective effects of progestin on the endometrium. 5 Regulatory hurdles have resulted in delays in initiation of the clinical trial which is now currently underway.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE